Pharma and biotech M&A
The largest deals rest on the most specialized evidence.
Clinical data, regulatory pathways, patent expiries and manufacturing quality decide pharma and biotech value. The pack plugs that evidence into the same review and valuation core — with exact citations throughout.
Planned. Industry packs are built only after the software baseline is proven with pilot customers, in the order shown. A design partner in this sector can help shape the pack.
Where these deals go wrong
Acquisitions and licensing deals for pharmaceutical and biotechnology assets and companies.
Clinical evidence read through a summary
What the data supports and what the deck says can differ.
An approval path with open questions
Regulatory risk is binary and lands on the timeline and the price.
A patent cliff inside the forecast
Exclusivity dates decide when revenue falls away.
The questions that decide the deal
- What does the clinical evidence actually support?
- What is the regulatory path and approval risk with the FDA or EMA?
- When do patents and exclusivity expire, and what happens to revenue then?
- Does manufacturing meet GMP standards?
How a pharma and biotech deal would run
An illustrative walk through the decision loop once the pack is built.
01 · Evidence
Trial registries, regulatory filings, patent data and manufacturing records join the document set.
02 · Finding
Clinical, regulatory, patent and quality findings are drafted with exact citations to filings and protocols.
03 · Review
Scientific, regulatory and legal reviewers decide in one workflow.
04 · Valuation
Approval timing and exclusivity feed the scenarios the deal team runs.
05 · Deal terms
Milestones, contingent payments and indemnities tied to the findings.
What it finds — and what that becomes in the deal
Illustrative examples of findings and the terms they turn into. Every real finding carries citations and a named reviewer.
- High severityExample
Key patent expires earlier than the forecast assumes
Patent record and the revenue forecast
Revised exclusivity case in the valuation
- Medium severityExample
Open manufacturing observations at a supplier site
Inspection records cited
Supply-continuity covenant
What carries over from the core
These parts of Pactlab apply to the sector as they are.
Evidence to valuation
The same evidence, finding, review and valuation skeleton.
Document citations
Exact citations for filings, protocols and agreements.
What the industry pack adds
New sources, finding types and valuation inputs — plugged into the unchanged core.
Clinical evidence
Adapters for trial registries and clinical data.
Regulatory pathway
FDA and EMA filings and approval risk as findings.
Patents and exclusivity
Patent-cliff and exclusivity analysis from patent data.
Manufacturing quality
GMP and manufacturing findings.
What you walk away with
Cited clinical and regulatory findings
Every claim tied to the filing or protocol it came from.
An exclusivity timeline
Patent and exclusivity dates in the valuation, not in an appendix.
Milestone-based terms
Contingent consideration linked to the risks behind it.
Questions buyers ask
Can we use Pactlab for a pharma and biotech deal today?
The pharma and biotech pack is planned, not built. Pactlab is proving its software baseline with pilot customers first. If the target has a software business, the software modules apply today — and design partners in pharma and biotech help decide what the pack reads and checks first.
Why is it fifth, given the deal sizes?
Almost none of today’s evidence sources or finding types apply, so it is the largest build. The core — evidence, review, citations and valuation — carries over unchanged.
Buying in pharma and biotech?
Design partners in this sector help decide what the pack reads and checks first. Talk to us.